Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Circulating Serum miRNA-Based Model to Predict Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Version 1 : Received: 1 July 2022 / Approved: 4 July 2022 / Online: 4 July 2022 (05:59:59 CEST)

How to cite: Puła, A.; Robak, P.; Jarych, D.; Mikulski, D.; Misiewicz, M.; Drozdz, I.; Fendler, W.; Szemraj, J.; Robak, T. A Circulating Serum miRNA-Based Model to Predict Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Preprints 2022, 2022070033 (doi: 10.20944/preprints202207.0033.v1). Puła, A.; Robak, P.; Jarych, D.; Mikulski, D.; Misiewicz, M.; Drozdz, I.; Fendler, W.; Szemraj, J.; Robak, T. A Circulating Serum miRNA-Based Model to Predict Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Preprints 2022, 2022070033 (doi: 10.20944/preprints202207.0033.v1).

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first year of diagnosis. Numerous studies investigating microRNA (miRNA) expression patterns suggest they may be good prognostic markers. The primary aim of this study was to analyze the expression of selected miRNAs in the serum of MM patients subsequently treated with bortezomib-based regimens and determine their potential to predict early mortality. The study was conducted in 69 prospectively-recruited patients with newly-diagnosed MM admitted to the Department of Hematology of the Copernicus Memorial Hospital, Lodz (Poland) between 2017 and 2021. Among them, 17 patients experienced death within 12 months of diagnosis. The expression of 31 selected miRNAs was determined using miRCURY LNA miRNA Custom PCR Panel. The obtained clinical data included patient characteristics on diagnosis, treatment regimen, response to treatment, and follow-up. Differential expression analysis found two miRNAs to be significantly downregulated in the early mortality group: hsa-miR-328-3p (fold change- FC: 0.72, p=0.0342) and hsa-miR-409-3p (FC: 0.49, p=0.0357). Univariate and multivariate logistic regression analyses were performed to assess the early mortality rate. The final model consisted of hsa-miR-409-3p, hsa-miR-328-3p, age and R-ISS 3. It yielded an area under the curve (AUC) of 0.863 (95%CI: 0.761-0.965) with 88.2% sensitivity and 77.5% specificity. Further external validation of our model is necessary to confirm its clinical value.

Keywords

multiple myeloma; early mortality; blood plasma; circulating miRNA; hematological malignancies; molecular biomarker; multiparametric model; prognosissurvival

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.